ESCMID

@ESCMID · Basel · joined 22 Jan 2010

The European Society of Clinical Microbiology and Infectious Diseases Improving the diagnosis, treatment and prevention of infection-related diseases

38 299Followers

3 849Following

17 986Posts total

10.1KViews on collected posts

Ultimi post

ESCMID@ESCMID6 Sep

⏳ Registration deadline extended! https://t.co/RLpfdzrZG9 Build practical clinical research skills at this onsite course, covering study design, bias reduction, scientific writing and the latest in clinical trial methodology. Registration closes on Tues, 15 Sep! https://t.co/ML 936 views · 3 likes · 1 reposts · 0 replies Open on X →

ESCMID@ESCMID5 Sep

🤝 Sepsis management meets antimicrobial stewardship in the ICU. ESICM & ESCMID come together for a webinar on balancing timely sepsis treatment with responsible antimicrobial use. 🗓️ 08 Sept | 16:00–17:00 CEST Join the livestream: https://t.co/BfafhyRP5c https://t.co/9Kt4GM7UI 1.5K views · 13 likes · 5 reposts · 0 replies Open on X →

ESCMID@ESCMID4 Sep

This online course addresses emerging antimicrobial resistance, virulence, and the critical role of anaerobes in infectious diseases, equipping participants with the knowledge to effectively work with this important group of organisms. Register today: https://t.co/wEuhhSU8hO htt 1.1K views · 2 likes · 2 reposts · 0 replies Open on X →

ESCMID@ESCMID3 Sep

https://t.co/20Rx12S3jz Watch Philip Packer highlight the focused nature of GAMRIC with a solution-oriented approach allowing funders to look for new opportunities and set their priorities based on the challenges we face today. Register for #GAMRIC2026: https://t.co/4Wc3DZmtIC 1.7K views · 0 likes · 0 reposts · 0 replies Open on X →

ESCMID@ESCMID2 Sep

🦴🦠 This online course focuses on implant-associated infections, with special emphasis on prosthetic joint and fracture-related infections from infectious diseases, microbiology, and orthopaedic perspectives. 💡 Learn more and sign up today: https://t.co/McNnoHo9VD https://t.co/XC 1.5K views · 10 likes · 3 reposts · 0 replies Open on X →

ESCMID@ESCMID23 Jan 2025

Enhance your skills in publishing your research manuscripts with this upcoming ESCMID Course organised by our journals @CMIJournal and CMI Communications! Attendants receive insights from journal editors and authors and participate in hands-on sessions. https://t.co/MZTfMTduH8 h 3.4K views · 7 likes · 4 reposts · 0 replies Open on X →

Rispetto ad account della stessa dimensione

5 post degli ultimi 90 giorni, accanto alla fascia di 10K–100K follower. copertura nella norma per la sua dimensione, reazione più debole della media.

Visualizzazioni mediane1 492questo account924mediana per 10K–100K

Copertura, %3.90%questo account3.62%mediana per 10K–100K

Interazione, %0.53%questo account1.52%mediana per 10K–100K

Metrica	Questo account	Mediana per 10K–100K	Rapporto
Visualizzazioni mediane per post	1 492	924	1.61×
Copertura (visualizzazioni ÷ follower)	3.90%	3.62%	1.08×
Tasso di interazione	0.53%	1.52%	0.35×

Altri account di questa fascia → Confronta con un altro account → Come sono costruiti questi parametri →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.4K23 Jan

1.5K2 Sep

1.7K3 Sep

1.1K4 Sep

1.5K5 Sep

9366 Sep

Last 6 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.35%23 Jan

0.87%2 Sep

0.00%3 Sep

0.37%4 Sep

1.25%5 Sep

0.53%6 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes53.0%35 in total

Reposts22.7%15 in total

Quotes4.5%3 in total

Bookmarks19.7%13 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.